Current pharmacological management of Alzheimer's disease and vascular dementia

Geriatrics and Aging

Volumn 9, Issue 1, 2006, Pages 22-28

  Hsiung, Ging Yuek Robin ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Donepezil; Galantamine; Memantine; Rivastigmine; Vascular dementia

Indexed keywords

ACETAZOLAMIDE; ALPHA TOCOPHEROL; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARUNDIC ACID; ATOMOXETINE; ATORVASTATIN; CHOLINESTERASE INHIBITOR; DOMPERIDONE; DONEPEZIL; FISH OIL; GALANTAMINE; HUPERZINE A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETASYN; LEUPRORELIN; MEMANTINE; MONOCLONAL ANTIBODY AAB 001; NERAMEXANE; NOOTROPIC AGENT; PLACEBO; PROKINETIC AGENT; RASAGILINE; RECOMBINANT ALPHA INTERFERON; RIVASTIGMINE; SIMVASTATIN; THIOCTIC ACID; TURMERIC; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID;

ALZHEIMER DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONFUSION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG URINE LEVEL; FOOD DRUG INTERACTION; FUNCTIONAL DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; MULTIINFARCT DEMENTIA; NAUSEA; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SLEEP DISORDER; STOMACH DISEASE; VOMITING;

EID: 32244446707     PISSN: 14888408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. CSHA. Canadian study of health and aging: study methods and prevalence of dementia. CMAJ 1994;150:899-913.
2. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997;278:1363-71.
3. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-24.
4. Feldman H, Levy AR, Hsiung GY, et al. A Canadian cohort study of cognitive impairment and related dementias (ACCORD): study methods and baseline results. Neuroepidemiology 2003;22:265-74.
5. Erkinjuntti T. Diagnosis and management of vascular cognitive impairment and dementia. J Neural Transm Suppl 2002:91-109.
6. Roman GC. Vascular dementia may be the most common form of dementia in the elderly. J Neurol Sci 2002;203:7-10.
7. McGeer PL, McGeer EG, Suzuki J, et al. Aging, Alzheimer's disease, and the cholinergic system of the basal forebrain. Neurology 1984;34:741-5.
8. Rossor MN, Iversen LL, Reynolds GP, et al. Neurochemical characteristics of early and late onset types of Alzheimer's disease. Br Med J (Clin Res Ed) 1984;288:961-4.
9. Arai H, Ichimiya Y, Kosaka K, et al. Neurotransmitter changes in early- and late-onset Alzheimer-type dementia. Prog Neuropsychopharmacol Biol Psychiatry 1992;16:883-90.
10. Hsiung G-YR, Feldman H. Pharmacological management of Alzheimer disease: an update. Geriatrics Aging 2004;7:47-50.
11. Hsiung G-YR, Loy-English I. Current therapy: a review of the cholinesterase inhibitors. BCMJ 2004;46:338-43.
12. Birks J, Grimley E, Iakovidou V, et al. Rivastigmine for Alzheimer's disease: the Cochrane Database of Systematic Reviews 2005:DOI:10.1002/14651858.CD001191.
13. Birks J, Harvey R. Donepezil for dementia due to Alzheimer's disease. The Cochrane Database of Systematic Reviews 2003; 3:DOI: 10.1002/14651858.CD001190.
14. Loy C, Schneider L. Galantamine for Alzheimer's disease. The Cochrane Database of Systematic Reviews 2004:DOI: 10.1002/14651858.CD001747.pub2.
15. Lanctot KL, Herrmann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003;169:557-64.
16. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-20.
17. Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001;49:1590-9.
18. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004;363:2105-15.
19. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379-88.
20. Wilcock G, Howe I, Coles H, et al. A longterm comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 2003;20:777-89.
21. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-41.
22. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-24.
23. Berman K, Brodaty H. Tocopherol (vitamin E) in Alzheimer's disease and other neurodegenerative disorders. CNS Drugs 2004;18:807-25.
24. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease: the Alzheimer's disease cooperative study. N Engl J Med 1997;336:1216-22.
25. Miller ER, 3rd, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:37-46.
26. Shobab L, Hsiung G-YR, Feldman H. The role of cholesterol in Alzheimer's disease. Lancet Neurol (in press).
27. Zandi PP, Sparks DL, Khachaturian AS, et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County study. Arch Gen Psychiatry 2005;62:217-24.
28. Rea TD, Breitner JC, Psaty BM, et al. Statin use and the risk of incident dementia: the Cardiovascular health study. Arch Neurol 2005;62:1047-51.
29. Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005;62:753-7.
30. Thal LJ, Carta A, Clarke WR, et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology 1996;47:705-11.
31. Aisen PS, Davis KL, Berg JD, et al. A randomized controlled trial of prednisone in Alzheimer's disease. Neurology 2000;54:588-93.
32. Mulnard RA, Corrada MM, Kawas CH. Estrogen replacement therapy, Alzheimer's disease, and mild cognitive impairment. Curr Neurol Neurosci Rep 2004;4:368-73.
33. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003;289:2819-26.
34. Couzin J. Halt of Celebrex study threatens drug's future, other trials. Science 2004;306:2170.
35. Thal LJ, Grundman M, Berg J, et al. Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. Neurology 2003;61:1498-502.
36. Thal LJ, Calvani M, Amato A, et al. A 1-year controlled trial of acetyl-l-carnitine in early-onset AD. Neurology 2000;55:805-10.
37. Iadecola C, Gorelick PB. Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke 2003;34:335-7.
38. Erkinjuntti T, Roman G, Gauthier S. Treatment of vascular dementia - evidence from clinical trials with cholinesterase inhibitors. J Neurol Sci 2004;226:63-6.
39. Black S, Roman GC, Geldmacher DS, et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multi-center, international, randomized, placebo-controlled clinical trial. Stroke 2003;34:2323-30.
40. Roman GC, Wilkinson DG, Doody RS, et al. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement Geriatr Cogn Disord 2005;20:338-44.
41. Kennedy SH, Konarski JZ, McIntyre R. A neuroimaging investigation of brain activity in major depressive disorder and bipolar disorder. ClinicalTrials.gov (recruiting); www.clinicaltrials.gov/ct (Accessed December 5, 2005).